🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 13 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 17/06/2016 | 90,46 | 91,24 | 85,88 | 86,73 | -4,07% | 5,93% | 2.658.900 |
| 16/06/2016 | 89,95 | 90,68 | 88,58 | 90,41 | -0,47% | 2,33% | 1.284.100 |
| 15/06/2016 | 91,35 | 91,98 | 90,40 | 90,84 | -0,58% | 1,73% | 1.083.200 |
| 14/06/2016 | 90,08 | 91,65 | 89,52 | 91,37 | +0,92% | 2,36% | 1.253.800 |
| 13/06/2016 | 91,24 | 92,47 | 90,06 | 90,54 | -1,04% | 2,64% | 1.203.300 |
| 10/06/2016 | 92,48 | 93,08 | 90,82 | 91,49 | -1,08% | 2,44% | 1.432.000 |
| 09/06/2016 | 94,00 | 94,55 | 92,18 | 92,49 | -2,22% | 2,52% | 1.191.800 |
| 08/06/2016 | 95,03 | 96,00 | 93,42 | 94,59 | -0,19% | 2,71% | 1.690.400 |
| 07/06/2016 | 95,22 | 95,85 | 93,56 | 94,77 | -1,37% | 2,40% | 1.852.000 |
| 06/06/2016 | 94,49 | 96,49 | 92,47 | 96,09 | +2,27% | 4,25% | 1.259.900 |
| 03/06/2016 | 95,62 | 95,69 | 92,62 | 93,96 | -1,94% | 3,21% | 1.473.300 |
| 02/06/2016 | 93,64 | 95,88 | 93,11 | 95,82 | +2,04% | 2,96% | 1.295.100 |
| 01/06/2016 | 92,90 | 94,35 | 92,68 | 93,90 | +0,81% | 1,80% | 1.433.000 |
| 31/05/2016 | 90,62 | 93,60 | 90,61 | 93,15 | +3,06% | 3,30% | 1.741.000 |
| 27/05/2016 | 89,28 | 90,49 | 88,37 | 90,38 | +1,33% | 2,37% | 1.109.500 |
| 26/05/2016 | 89,05 | 89,93 | 87,24 | 89,19 | -0,41% | 3,02% | 1.325.300 |
| 25/05/2016 | 88,99 | 89,73 | 88,14 | 89,56 | +1,29% | 1,79% | 1.598.600 |
| 24/05/2016 | 83,70 | 88,44 | 83,62 | 88,42 | +4,74% | 5,76% | 1.503.000 |
| 23/05/2016 | 84,28 | 85,60 | 83,30 | 84,42 | -0,33% | 2,73% | 1.223.800 |
| 20/05/2016 | 81,03 | 85,00 | 80,55 | 84,70 | +4,55% | 5,49% | 1.659.100 |
| 19/05/2016 | 80,89 | 82,29 | 80,25 | 81,01 | -0,86% | 2,52% | 1.674.400 |
| 18/05/2016 | 80,27 | 82,25 | 80,27 | 81,71 | +1,24% | 2,47% | 1.926.300 |
| 17/05/2016 | 81,46 | 82,49 | 80,41 | 80,71 | -1,74% | 2,55% | 2.166.700 |
| 16/05/2016 | 81,64 | 83,22 | 81,38 | 82,14 | +0,93% | 2,25% | 2.075.500 |
| 13/05/2016 | 81,79 | 83,03 | 81,06 | 81,38 | -0,88% | 2,41% | 1.120.000 |
| 12/05/2016 | 84,24 | 84,83 | 80,58 | 82,10 | -1,83% | 5,05% | 2.047.100 |
| 11/05/2016 | 88,96 | 89,07 | 83,53 | 83,63 | -6,12% | 6,23% | 1.662.700 |
| 10/05/2016 | 88,58 | 89,10 | 86,26 | 89,08 | +1,16% | 3,21% | 2.095.100 |
| 09/05/2016 | 85,54 | 88,94 | 85,51 | 88,06 | +2,95% | 4,01% | 1.800.800 |
| 06/05/2016 | 83,23 | 85,66 | 82,95 | 85,54 | +1,83% | 3,26% | 1.999.300 |